Ricardo Fonseca Oliveira Suruagy Motta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ricardo Fonseca Oliveira Suruagy Motta has a total of 156 co-authors. Here are the top co-authors by number of shared publications:
- Marcos Danillo Peixoto Oliveira
Universidade Federal de Sao Paulo, Brasil
5 shared publications - Evandro Martins Filho
University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine
4 shared publications - Karlos Daniell Araújo dos Santos
Universidade Federal de Roraima, Brasil
4 shared publications - Adriano Caixeta
Postgraduate Program in Cardiology, Universidade Federal de São Paulo (UNIFESP), São Paulo 04024-000, SP, Brazil
3 shared publications Evandro Martins Filho
3 shared publicationsBeatriz Calaça de Pádua Carvalho
Department of Medicine, Cesmac University Center
2 shared publications
Latest Publications
- 20 October 2026
- Published by SAGE Publications in Lupus
Sodium-glucose cotransporter 2 inhibitors in patients with systemic lupus erythematosus and lupus nephritis: A systematic review and meta-analysis
Introduction: Systemic Lupus Erythematosus (SLE) and lupus nephritis (LN) carry substantial cardiorenal risks. Conventional immunosuppressive therapies primarily target inflammation but leave a burden of residual renal and metabolic damage. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) provide clear cardiorenal protection in general populations, but data specific to SLE remains limited. This systematic review and meta-analysis evaluated the efficacy and safety of SGLT2i in patients with SLE and LN. Methods: Comprehensive searches across five electronic databases (PubMed, Cochrane CENTRAL, Web of Science, Embase, and Scopus) were conducted up to April 2026 to identify randomized controlled trials (RCTs) and observational studies assessing SGLT2i in adult SLE/LN patients. Random-effects meta-analyses were performed to synthesize cardiorenal and safety outcomes using R Software. Results: Six studies published between 2024 and 2025 were included. Pooled data demonstrated that SGLT2i use was associated with a significant improvement in estimated glomerular filtration rate (eGFR) compared to controls (MD: 4.02; 95% CI: 1.39–6.65; I 2 = 60.1%). SGLT2i significantly reduced the risks of progression to end-stage kidney disease (RR: 0.37; 95% CI: 0.25–0.56; I 2 = 11.0%), heart failure development (RR: 0.65; 95% CI: 0.56–0.75; I 2 = 0.0%), incident lupus nephritis (RR: 0.58; 95% CI: 0.44–0.76; I 2 = 0.0%), and re-hospitalizations (RR: 0.67; 95% CI: 0.57–0.79; I 2 = 0.0%). Furthermore, a significant reduction in all-cause mortality was observed (RR: 0.55; 95% CI: 0.36–0.86; I 2 = 76.2%). SGLT2i treatment demonstrated an acceptable safety profile across the included cohorts. The certainty of evidence for these findings was rated as low to very low, and results remain vulnerable to residual confounding from variables such as disease activity, corticosteroid burden, and immunosuppressive regimen. Conclusion: Preliminary exploratory evidence suggests potential associations between SGLT2 inhibitors and cardiorenal outcomes in lupus nephritis. Given the low certainty of evidence and vulnerability to residual confounding from disease-specific variables, these hypothesis-generating findings require confirmation in well-designed randomized controlled trials.
- 20 October 2026
- Published by SAGE Publications in Lupus
Sodium-glucose cotransporter 2 inhibitors in patients with systemic lupus erythematosus and lupus nephritis: A systematic review and meta-analysis
Introduction: Systemic Lupus Erythematosus (SLE) and lupus nephritis (LN) carry substantial cardiorenal risks. Conventional immunosuppressive therapies primarily target inflammation but leave a burden of residual renal and metabolic damage. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) provide clear cardiorenal protection in general populations, but data specific to SLE remains limited. This systematic review and meta-analysis evaluated the efficacy and safety of SGLT2i in patients with SLE and LN. Methods: Comprehensive searches across five electronic databases (PubMed, Cochrane CENTRAL, Web of Science, Embase, and Scopus) were conducted up to April 2026 to identify randomized controlled trials (RCTs) and observational studies assessing SGLT2i in adult SLE/LN patients. Random-effects meta-analyses were performed to synthesize cardiorenal and safety outcomes using R Software. Results: Six studies published between 2024 and 2025 were included. Pooled data demonstrated that SGLT2i use was associated with a significant improvement in estimated glomerular filtration rate (eGFR) compared to controls (MD: 4.02; 95% CI: 1.39–6.65; I 2 = 60.1%). SGLT2i significantly reduced the risks of progression to end-stage kidney disease (RR: 0.37; 95% CI: 0.25–0.56; I 2 = 11.0%), heart failure development (RR: 0.65; 95% CI: 0.56–0.75; I 2 = 0.0%), incident lupus nephritis (RR: 0.58; 95% CI: 0.44–0.76; I 2 = 0.0%), and re-hospitalizations (RR: 0.67; 95% CI: 0.57–0.79; I 2 = 0.0%). Furthermore, a significant reduction in all-cause mortality was observed (RR: 0.55; 95% CI: 0.36–0.86; I 2 = 76.2%). SGLT2i treatment demonstrated an acceptable safety profile across the included cohorts. The certainty of evidence for these findings was rated as low to very low, and results remain vulnerable to residual confounding from variables such as disease activity, corticosteroid burden, and immunosuppressive regimen. Conclusion: Preliminary exploratory evidence suggests potential associations between SGLT2 inhibitors and cardiorenal outcomes in lupus nephritis. Given the low certainty of evidence and vulnerability to residual confounding from disease-specific variables, these hypothesis-generating findings require confirmation in well-designed randomized controlled trials.
- Open Access
- 30 September 2026
- Published by Sociedade Brasileira de Cardiologia in International Journal of Cardiovascular Sciences
- Vol. 39
Percutaneous Coronary Intervention With Ridaforolimus-Eluting Stents in Patients With Coronary Artery Disease: A Systematic Review and Single-Arm Meta-Analysis
Background: The ridaforolimus-eluting stent (RES) is a new-generation drug-eluting stent (DES) featuring thin struts and a durable polymer, designed to provide a high therapeutic-to-toxicity margin. However, its long-term clinical performance remains uncertain. Methods: We conducted a systematic review and meta-analysis following Cochrane and PRISMA guidelines. PubMed, Embase, and Cochrane databases were searched for randomized controlled trials (RCTs) and prospective non-RCT studies evaluating RES in patients with coronary artery disease (CAD). Outcomes were expressed as event rates using a generalized [...] Abstract Background: The ridaforolimus-eluting stent (RES) is a new-generation drug-eluting stent (DES) featuring thin struts and a durable polymer, designed to provide a high therapeutic-to-toxicity margin. However, its long-term clinical performance remains uncertain. Methods: We conducted a systematic review and meta-analysis following Cochrane and PRISMA guidelines. PubMed, Embase, and Cochrane databases were searched for randomized controlled trials (RCTs) and prospective non-RCT studies evaluating RES in patients with coronary artery disease (CAD). Outcomes were expressed as event rates using a generalized
- 30 September 2026
- Published by Sociedade Brasileira de Cardiologia in International Journal of Cardiovascular Sciences
- Vol. 39
Open AccessPercutaneous Coronary Intervention With Ridaforolimus-Eluting Stents in Patients With Coronary Artery Disease: A Systematic Review and Single-Arm Meta-Analysis
Background: The ridaforolimus-eluting stent (RES) is a new-generation drug-eluting stent (DES) featuring thin struts and a durable polymer, designed to provide a high therapeutic-to-toxicity margin. However, its long-term clinical performance remains uncertain. Methods: We conducted a systematic review and meta-analysis following Cochrane and PRISMA guidelines. PubMed, Embase, and Cochrane databases were searched for randomized controlled trials (RCTs) and prospective non-RCT studies evaluating RES in patients with coronary artery disease (CAD). Outcomes were expressed as event rates using a generalized [...] Abstract Background: The ridaforolimus-eluting stent (RES) is a new-generation drug-eluting stent (DES) featuring thin struts and a durable polymer, designed to provide a high therapeutic-to-toxicity margin. However, its long-term clinical performance remains uncertain. Methods: We conducted a systematic review and meta-analysis following Cochrane and PRISMA guidelines. PubMed, Embase, and Cochrane databases were searched for randomized controlled trials (RCTs) and prospective non-RCT studies evaluating RES in patients with coronary artery disease (CAD). Outcomes were expressed as event rates using a generalized
- 18 August 2026
- Published by Wiley in Catheterization and Cardiovascular Interventions
Propofol‐Based Lubrication to Overcome Equipment Friction in Chronic Total Occlusion PCI: The Propoglide Technique
Background: CTO PCI success depends on consistent equipment performance. Equipment friction (Stingray guidewire lumen fatigue, microcatheter internal lumen friction, and retrograde externalization friction) causes procedural delay and failure. The standard solution is device exchange, which is time‐consuming and adds cost. To our knowledge, no published technique addresses CTO‐specific equipment friction with an alternative to Rotaglide, which is unavailable in most countries. Aims: This report aims to describe and illustrate the Propoglide technique, the use of propofol 1% lipid emulsion as an off‐label lubricant to overcome equipment friction in CTO PCI across three clinically distinct scenarios. Methods: We describe the Propoglide technique: propofol 1% lipid emulsion (soybean oil carrier) applied as an off‐label lubricant across three CTO PCI scenarios: (A) Stingray balloon guidewire lumen, (B) microcatheter inner lumen, and (C) retrograde externalization. Device‐specific dead space estimates for common coronary microcatheters guide propofol volume selection. Three illustrative cases demonstrate clinical application. Results: Propofol lubrication resolved friction‐related failure in all illustrated cases, restoring device function within a single application without device exchange. Propofol volumes ranged from 0.3 to 0.8 mL (3–8 mg), pharmacologically negligible relative to sedation doses. No adverse events were observed in the illustrative cases. Conclusions: Propofol 1% emulsion provides practical, safe lubrication for CTO PCI equipment across three clinically distinct friction scenarios, with particular relevance in settings where dedicated lubricants and externalization wires are unavailable. Prospective validation is warranted.
- 18 August 2026
- Published by Wiley in Catheterization and Cardiovascular Interventions
Propofol‐Based Lubrication to Overcome Equipment Friction in Chronic Total Occlusion PCI: The Propoglide Technique
Background: CTO PCI success depends on consistent equipment performance. Equipment friction (Stingray guidewire lumen fatigue, microcatheter internal lumen friction, and retrograde externalization friction) causes procedural delay and failure. The standard solution is device exchange, which is time‐consuming and adds cost. To our knowledge, no published technique addresses CTO‐specific equipment friction with an alternative to Rotaglide, which is unavailable in most countries. Aims: This report aims to describe and illustrate the Propoglide technique, the use of propofol 1% lipid emulsion as an off‐label lubricant to overcome equipment friction in CTO PCI across three clinically distinct scenarios. Methods: We describe the Propoglide technique: propofol 1% lipid emulsion (soybean oil carrier) applied as an off‐label lubricant across three CTO PCI scenarios: (A) Stingray balloon guidewire lumen, (B) microcatheter inner lumen, and (C) retrograde externalization. Device‐specific dead space estimates for common coronary microcatheters guide propofol volume selection. Three illustrative cases demonstrate clinical application. Results: Propofol lubrication resolved friction‐related failure in all illustrated cases, restoring device function within a single application without device exchange. Propofol volumes ranged from 0.3 to 0.8 mL (3–8 mg), pharmacologically negligible relative to sedation doses. No adverse events were observed in the illustrative cases. Conclusions: Propofol 1% emulsion provides practical, safe lubrication for CTO PCI equipment across three clinically distinct friction scenarios, with particular relevance in settings where dedicated lubricants and externalization wires are unavailable. Prospective validation is warranted.
- 13 August 2026
- Published by Wiley in Catheterization and Cardiovascular Interventions
Percutaneous Coronary Stentectomy: Redefining Stent Failure Management in the Modern Era
Percutaneous coronary stentectomy, intentional retrieval of a fully deployed coronary stent, has evolved from anecdotal salvage to a structured interventional strategy. It addresses scenarios where a deployed stent causes ongoing complications: malapposition, longitudinal deformation, or excessive aorto‐ostial protrusion leading to restenosis, thrombosis, or interference with structural heart interventions. We performed a narrative review of the published literature on intentional percutaneous coronary stent retrieval, supplemented by five illustrative cases from three academic centers representing acute, subacute, and late retrieval scenarios. Stentectomy was feasible across acute and late settings. Snare‐based retrieval through guide extension catheters was the predominant approach; stents with three or fewer inter‐ring connectors allowed more predictable extraction. Intravascular ultrasound was essential for procedural planning, confirmation of complete removal, and post‐extraction management. Drug‐coated balloons enabled metal‐free revascularization after stent removal. A novel reverse hairpin‐assisted snare extraction technique facilitated pre‐TAVR stent retrieval in one case. The Side Flap technique and stentectomy emerged as complementary strategies for managing excessive aorto‐ostial protrusion. Percutaneous coronary stentectomy is a feasible strategy for selected clinical scenarios, with intravascular imaging central to procedural planning and assessment. When performed with appropriate technique and Heart Team evaluation, it can address stent complications, restore coronary access, and enable metal‐free revascularization.
- 13 August 2026
- Published by Wiley in Catheterization and Cardiovascular Interventions
Percutaneous Coronary Stentectomy: Redefining Stent Failure Management in the Modern Era
Percutaneous coronary stentectomy, intentional retrieval of a fully deployed coronary stent, has evolved from anecdotal salvage to a structured interventional strategy. It addresses scenarios where a deployed stent causes ongoing complications: malapposition, longitudinal deformation, or excessive aorto‐ostial protrusion leading to restenosis, thrombosis, or interference with structural heart interventions. We performed a narrative review of the published literature on intentional percutaneous coronary stent retrieval, supplemented by five illustrative cases from three academic centers representing acute, subacute, and late retrieval scenarios. Stentectomy was feasible across acute and late settings. Snare‐based retrieval through guide extension catheters was the predominant approach; stents with three or fewer inter‐ring connectors allowed more predictable extraction. Intravascular ultrasound was essential for procedural planning, confirmation of complete removal, and post‐extraction management. Drug‐coated balloons enabled metal‐free revascularization after stent removal. A novel reverse hairpin‐assisted snare extraction technique facilitated pre‐TAVR stent retrieval in one case. The Side Flap technique and stentectomy emerged as complementary strategies for managing excessive aorto‐ostial protrusion. Percutaneous coronary stentectomy is a feasible strategy for selected clinical scenarios, with intravascular imaging central to procedural planning and assessment. When performed with appropriate technique and Heart Team evaluation, it can address stent complications, restore coronary access, and enable metal‐free revascularization.
- Open Access
- 4 July 2026
- Published by Springer Nature in SN Comprehensive Clinical Medicine
- Vol. 8 (1)
Impact of Diabetes on Long-Term Outcomes After Percutaneous Intervention for Coronary Bifurcation Lesions: A Systematic Review and Meta-analysis
Introduction: Percutaneous coronary intervention (PCI) in coronary bifurcation lesions is technically complex and associated with higher adverse event rates. Diabetes mellitus (DM) worsens outcomes through diffuse atherosclerosis and a prothrombotic, proinflammatory state, even with drug-eluting stents. However, the specific impact of DM on bifurcation PCI outcomes remains unclear. This study aims to evaluate the effect of DM on long-term clinical outcomes after PCI for coronary bifurcation lesions through a systematic review and meta-analysis. Methods: We conducted a systematic review and meta-analysis following PRISMA guidelines (PROSPERO-registered). PubMed, Cochrane, Web of Science, and Scopus were searched through August 2025. Observational studies comparing the clinical impact of diabetes mellitus in patients with coronary bifurcation lesions were eligible if they reported mortality, myocardial infarction (MI), or bleeding. Risk ratios (RRs) with 95% confidence intervals (CIs) were calculated using random-effects models. Results: Five retrospective studies and one prospective study comprising 12,494 patients undergoing percutaneous coronary intervention (PCI) for coronary bifurcation lesions (involving both left main and non–left main locations) were included, with diabetes prevalence ranging from 33% to 50%. Across all follow-up periods, diabetes was consistently associated with worse outcomes. Diabetic patients had significantly higher risks of MACE from 9 months to 2 years (RR range 1.73–1.92) and increased myocardial infarction rates up to 5 years (RR range 1.90–2.16). Diabetes was also associated with higher cardiac mortality at 9 months (RR 1.96) and increased target lesion revascularization from 9 months to 2 years (RR range 1.61–1.82). No significant association was observed between diabetes and stent thrombosis. Conclusion: In patients undergoing PCI for coronary bifurcation lesions, diabetes mellitus is associated with significantly worse long-term clinical outcomes, including higher rates of MACE, myocardial infarction and repeat revascularization. Despite contemporary drug-eluting stent use, diabetic patients remain at increased ischemic risk, underscoring the need for tailored revascularization strategies and optimized metabolic and procedural management in this high-risk population.
- 4 July 2026
- Published by Springer Nature in SN Comprehensive Clinical Medicine
- Vol. 8 (1)
Open AccessImpact of Diabetes on Long-Term Outcomes After Percutaneous Intervention for Coronary Bifurcation Lesions: A Systematic Review and Meta-analysis
Introduction: Percutaneous coronary intervention (PCI) in coronary bifurcation lesions is technically complex and associated with higher adverse event rates. Diabetes mellitus (DM) worsens outcomes through diffuse atherosclerosis and a prothrombotic, proinflammatory state, even with drug-eluting stents. However, the specific impact of DM on bifurcation PCI outcomes remains unclear. This study aims to evaluate the effect of DM on long-term clinical outcomes after PCI for coronary bifurcation lesions through a systematic review and meta-analysis. Methods: We conducted a systematic review and meta-analysis following PRISMA guidelines (PROSPERO-registered). PubMed, Cochrane, Web of Science, and Scopus were searched through August 2025. Observational studies comparing the clinical impact of diabetes mellitus in patients with coronary bifurcation lesions were eligible if they reported mortality, myocardial infarction (MI), or bleeding. Risk ratios (RRs) with 95% confidence intervals (CIs) were calculated using random-effects models. Results: Five retrospective studies and one prospective study comprising 12,494 patients undergoing percutaneous coronary intervention (PCI) for coronary bifurcation lesions (involving both left main and non–left main locations) were included, with diabetes prevalence ranging from 33% to 50%. Across all follow-up periods, diabetes was consistently associated with worse outcomes. Diabetic patients had significantly higher risks of MACE from 9 months to 2 years (RR range 1.73–1.92) and increased myocardial infarction rates up to 5 years (RR range 1.90–2.16). Diabetes was also associated with higher cardiac mortality at 9 months (RR 1.96) and increased target lesion revascularization from 9 months to 2 years (RR range 1.61–1.82). No significant association was observed between diabetes and stent thrombosis. Conclusion: In patients undergoing PCI for coronary bifurcation lesions, diabetes mellitus is associated with significantly worse long-term clinical outcomes, including higher rates of MACE, myocardial infarction and repeat revascularization. Despite contemporary drug-eluting stent use, diabetic patients remain at increased ischemic risk, underscoring the need for tailored revascularization strategies and optimized metabolic and procedural management in this high-risk population.
- 3 April 2026
- Published by Taylor & Francis in Future Cardiology
- Vol. 22 (4) , 391-404
Granulocyte colony stimulating factor for acute myocardial infarction: an updated systematic review and meta-analysis of randomized controlled trials
Granulocyte Colony-Stimulating Factor (G-CSF) has been explored as a therapy to enhance myocardial repair after acute myocardial infarction (AMI). Earlier meta-analyses of randomized controlled trials (RCTs) reported no significant improvement but recently published studies warranted an updated synthesis. We searched PubMed, Embase, Cochrane Library, and Web of Science for RCTs comparing G-CSF with placebo or standard care in AMI. Primary outcomes were left ventricular end-diastolic volume (LVEDV), left ventricular end-systolic volume (LVESV), and left ventricular ejection fraction (LVEF). Secondary outcomes were mortality, reinfarction, restenosis, and revascularization. Eleven RCTs encompassing 1,073 participants were included. G-CSF significantly reduced LVEDV in echocardiography studies (MD: -4.39 mL; 95% CI -6.80, -1.98; p < 0.001), whereas no effect was observed in MRI studies (MD: -0.19 mL; 95% CI -7.22, 6.84; p = 0.958). LVEF improved in the echocardiography subgroup (MD: 6.76%; 95% CI 1.62, 11.90; p = 0.010) but not in the MRI subgroup (MD: -0.08%; 95% CI -2.38, 2.22; p = 0.947). LVESV showed no significant differences. No effects were seen for mortality, reinfarction, restenosis, or revascularization. G-CSF may confer structural benefits detectable by echocardiography, yet clinical outcomes remain unchanged. Larger, high-quality trials are needed to define its therapeutic role.
- 3 April 2026
- Published by Taylor & Francis in Future Cardiology
- Vol. 22 (4) , 391-404
Granulocyte colony stimulating factor for acute myocardial infarction: an updated systematic review and meta-analysis of randomized controlled trials
Granulocyte Colony-Stimulating Factor (G-CSF) has been explored as a therapy to enhance myocardial repair after acute myocardial infarction (AMI). Earlier meta-analyses of randomized controlled trials (RCTs) reported no significant improvement but recently published studies warranted an updated synthesis. We searched PubMed, Embase, Cochrane Library, and Web of Science for RCTs comparing G-CSF with placebo or standard care in AMI. Primary outcomes were left ventricular end-diastolic volume (LVEDV), left ventricular end-systolic volume (LVESV), and left ventricular ejection fraction (LVEF). Secondary outcomes were mortality, reinfarction, restenosis, and revascularization. Eleven RCTs encompassing 1,073 participants were included. G-CSF significantly reduced LVEDV in echocardiography studies (MD: -4.39 mL; 95% CI -6.80, -1.98; p < 0.001), whereas no effect was observed in MRI studies (MD: -0.19 mL; 95% CI -7.22, 6.84; p = 0.958). LVEF improved in the echocardiography subgroup (MD: 6.76%; 95% CI 1.62, 11.90; p = 0.010) but not in the MRI subgroup (MD: -0.08%; 95% CI -2.38, 2.22; p = 0.947). LVESV showed no significant differences. No effects were seen for mortality, reinfarction, restenosis, or revascularization. G-CSF may confer structural benefits detectable by echocardiography, yet clinical outcomes remain unchanged. Larger, high-quality trials are needed to define its therapeutic role.
- 13 February 2026
- Published by Springer Nature in Sleep and Breathing
- Vol. 30 (1) , 47
Breathe poorly, recover worse? The impact of obstructive sleep apnea on cardiac surgery outcomes – an updated systematic review and meta-analysis
- 13 February 2026
- Published by Springer Nature in Sleep and Breathing
- Vol. 30 (1) , 47
Breathe poorly, recover worse? The impact of obstructive sleep apnea on cardiac surgery outcomes – an updated systematic review and meta-analysis
- 3 February 2026
- Published by Elsevier in Clinical Imaging
- Vol. 131, 110743
Pooled diagnostic accuracy of 68Ga-pentixafor PET/CT for aldosterone-producing lesions in primary aldosteronism
- 3 February 2026
- Published by Elsevier in Clinical Imaging
- Vol. 131, 110743
Pooled diagnostic accuracy of 68Ga-pentixafor PET/CT for aldosterone-producing lesions in primary aldosteronism